COVID-19-Associated cardiac pathology at the postmortem evaluation : a collaborative systematic review
Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved..
BACKGROUND: Many postmortem studies address the cardiovascular effects of COVID-19 and provide valuable information, but are limited by their small sample size.
OBJECTIVES: The aim of this systematic review is to better understand the various aspects of the cardiovascular complications of COVID-19 by pooling data from a large number of autopsy studies.
DATA SOURCES: We searched the online databases Ovid EBM Reviews, Ovid Embase, Ovid Medline, Scopus, and Web of Science for concepts of autopsy or histopathology combined with COVID-19, published between database inception and February 2021. We also searched for unpublished manuscripts using the medRxiv services operated by Cold Spring Harbor Laboratory.
STUDY ELIGIBILITY CRITERIA: Articles were considered eligible for inclusion if they reported human postmortem cardiovascular findings among individuals with a confirmed SARS coronavirus type 2 (CoV-2) infection.
PARTICIPANTS: Confirmed COVID-19 patients with post-mortem cardiovascular findings.
INTERVENTIONS: None.
METHODS: Studies were individually assessed for risk of selection, detection, and reporting biases. The median prevalence of different autopsy findings with associated interquartile ranges (IQRs).
RESULTS: This review cohort contained 50 studies including 548 hearts. The median age of the deceased was 69 years. The most prevalent acute cardiovascular findings were myocardial necrosis (median: 100.0%; IQR, 20%-100%; number of studies = 9; number of patients = 64) and myocardial oedema (median: 55.5%; IQR, 19.5%-92.5%; number of studies = 4; number of patients = 46). The median reported prevalence of extensive, focal active, and multifocal myocarditis were all 0.0%. The most prevalent chronic changes were myocyte hypertrophy (median: 69.0%; IQR, 46.8%-92.1%) and fibrosis (median: 35.0%; IQR, 35.0%-90.5%). SARS-CoV-2 was detected in the myocardium with median prevalence of 60.8% (IQR 40.4-95.6%).
CONCLUSIONS: Our systematic review confirmed the high prevalence of acute and chronic cardiac pathologies in COVID-19 and SARS-CoV-2 cardiac tropism, as well as the low prevalence of myocarditis in COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 28(2022), 8 vom: 10. Aug., Seite 1066-1075 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 26.07.2022 Date Revised 26.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cmi.2022.03.021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338698647 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338698647 | ||
| 003 | DE-627 | ||
| 005 | 20231226001242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cmi.2022.03.021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1128.xml |
| 035 | |a (DE-627)NLM338698647 | ||
| 035 | |a (NLM)35339672 | ||
| 035 | |a (PII)S1198-743X(22)00160-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Almamlouk, Raghed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19-Associated cardiac pathology at the postmortem evaluation |b a collaborative systematic review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.07.2022 | ||
| 500 | |a Date Revised 26.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Many postmortem studies address the cardiovascular effects of COVID-19 and provide valuable information, but are limited by their small sample size | ||
| 520 | |a OBJECTIVES: The aim of this systematic review is to better understand the various aspects of the cardiovascular complications of COVID-19 by pooling data from a large number of autopsy studies | ||
| 520 | |a DATA SOURCES: We searched the online databases Ovid EBM Reviews, Ovid Embase, Ovid Medline, Scopus, and Web of Science for concepts of autopsy or histopathology combined with COVID-19, published between database inception and February 2021. We also searched for unpublished manuscripts using the medRxiv services operated by Cold Spring Harbor Laboratory | ||
| 520 | |a STUDY ELIGIBILITY CRITERIA: Articles were considered eligible for inclusion if they reported human postmortem cardiovascular findings among individuals with a confirmed SARS coronavirus type 2 (CoV-2) infection | ||
| 520 | |a PARTICIPANTS: Confirmed COVID-19 patients with post-mortem cardiovascular findings | ||
| 520 | |a INTERVENTIONS: None | ||
| 520 | |a METHODS: Studies were individually assessed for risk of selection, detection, and reporting biases. The median prevalence of different autopsy findings with associated interquartile ranges (IQRs) | ||
| 520 | |a RESULTS: This review cohort contained 50 studies including 548 hearts. The median age of the deceased was 69 years. The most prevalent acute cardiovascular findings were myocardial necrosis (median: 100.0%; IQR, 20%-100%; number of studies = 9; number of patients = 64) and myocardial oedema (median: 55.5%; IQR, 19.5%-92.5%; number of studies = 4; number of patients = 46). The median reported prevalence of extensive, focal active, and multifocal myocarditis were all 0.0%. The most prevalent chronic changes were myocyte hypertrophy (median: 69.0%; IQR, 46.8%-92.1%) and fibrosis (median: 35.0%; IQR, 35.0%-90.5%). SARS-CoV-2 was detected in the myocardium with median prevalence of 60.8% (IQR 40.4-95.6%) | ||
| 520 | |a CONCLUSIONS: Our systematic review confirmed the high prevalence of acute and chronic cardiac pathologies in COVID-19 and SARS-CoV-2 cardiac tropism, as well as the low prevalence of myocarditis in COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cardiac pathology | |
| 650 | 4 | |a Myocarditis | |
| 650 | 4 | |a Postmortem | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Systematic review | |
| 700 | 1 | |a Kashour, Tarek |e verfasserin |4 aut | |
| 700 | 1 | |a Obeidat, Sawsan |e verfasserin |4 aut | |
| 700 | 1 | |a Bois, Melanie C |e verfasserin |4 aut | |
| 700 | 1 | |a Maleszewski, Joseph J |e verfasserin |4 aut | |
| 700 | 1 | |a Omrani, Osama A |e verfasserin |4 aut | |
| 700 | 1 | |a Tleyjeh, Rana |e verfasserin |4 aut | |
| 700 | 1 | |a Berbari, Elie |e verfasserin |4 aut | |
| 700 | 1 | |a Chakhachiro, Zaher |e verfasserin |4 aut | |
| 700 | 1 | |a Zein-Sabatto, Bassel |e verfasserin |4 aut | |
| 700 | 1 | |a Gerberi, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Tleyjeh, Imad M |e verfasserin |4 aut | |
| 700 | 0 | |a Cardiac Autopsy in COVID-19 Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Paniz Mondolfi, Alberto E |e verfasserin |4 aut | |
| 700 | 1 | |a Finn, Aloke V |e verfasserin |4 aut | |
| 700 | 1 | |a Duarte-Neto, Amaro Nunes |e verfasserin |4 aut | |
| 700 | 1 | |a Rapkiewicz, Amy V |e verfasserin |4 aut | |
| 700 | 1 | |a Frustaci, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Keresztesi, Arthur-Atilla |e verfasserin |4 aut | |
| 700 | 1 | |a Hanley, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Märkl, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Lardi, Christelle |e verfasserin |4 aut | |
| 700 | 1 | |a Bryce, Clare |e verfasserin |4 aut | |
| 700 | 1 | |a Lindner, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Aguiar, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Westermann, Dirk |e verfasserin |4 aut | |
| 700 | 1 | |a Stroberg, Edana |e verfasserin |4 aut | |
| 700 | 1 | |a Duval, Eric J |e verfasserin |4 aut | |
| 700 | 1 | |a Youd, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Bulfamante, Gaetano Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Salmon, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Auer, Johann |e verfasserin |4 aut | |
| 700 | 1 | |a Maleszewski, Joseph J |e verfasserin |4 aut | |
| 700 | 1 | |a Hirschbühl, Klaus |e verfasserin |4 aut | |
| 700 | 1 | |a Absil, Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Barton, Lisa M |e verfasserin |4 aut | |
| 700 | 1 | |a Ferraz da Silva, Luiz Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Luiza |e verfasserin |4 aut | |
| 700 | 1 | |a Dolhnikoff, Marisa |e verfasserin |4 aut | |
| 700 | 1 | |a Lammens, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Bois, Melanie C |e verfasserin |4 aut | |
| 700 | 1 | |a Osborn, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Remmelink, Myriam |e verfasserin |4 aut | |
| 700 | 1 | |a Nascimento Saldiva, Paulo Hilario |e verfasserin |4 aut | |
| 700 | 1 | |a Jorens, Philippe G |e verfasserin |4 aut | |
| 700 | 1 | |a Craver, Randall |e verfasserin |4 aut | |
| 700 | 1 | |a Aparecida de Almeida Monteiro, Renata |e verfasserin |4 aut | |
| 700 | 1 | |a Scendoni, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Mukhopadhyay, Sanjay |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Tadaki |e verfasserin |4 aut | |
| 700 | 1 | |a Mauad, Thais |e verfasserin |4 aut | |
| 700 | 1 | |a Fracasso, Tony |e verfasserin |4 aut | |
| 700 | 1 | |a Grimes, Zachary |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases |d 1995 |g 28(2022), 8 vom: 10. Aug., Seite 1066-1075 |w (DE-627)NLM094580014 |x 1469-0691 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:8 |g day:10 |g month:08 |g pages:1066-1075 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cmi.2022.03.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 8 |b 10 |c 08 |h 1066-1075 | ||